AIM ImmunoTech Net Income Per Share Over Time
| AIM Stock | USD 0.22 0 2.23% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out AIM ImmunoTech Performance and AIM ImmunoTech Correlation. AIM |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Per Share Analysis
Compare AIM ImmunoTech and related stocks such as Aptorum Group, Applied Molecular, and Fresh Tracks Therapeutics Net Income Per Share Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APM | (0.8459) | (0.8459) | (0.8459) | (0.8459) | (0.8459) | (0.8459) | (0.8459) | (0.8459) | (5.3142) | (7.1891) | 2.2697 | (7.2182) | (14.8885) | (0.6248) | (0.66) |
| BCDA | 0.376 | 906 | 28.6089 | 1.7822 | 20.5011 | 27.8595 | (166) | (43.5418) | (48.7971) | (39.382) | (22.2435) | (11.1904) | (10.0838) | (8.1948) | (8.6) |
| VRAX | (0.7043) | (0.7043) | (0.7043) | (0.7043) | (0.7043) | (0.7043) | (0.7043) | (0.7043) | (0.7043) | (0.7043) | (0.5723) | (1.5024) | (5.1341) | (3.356) | (3.52) |
| REVB | (0.4199) | (0.4199) | (0.4199) | (0.4199) | (0.4199) | (0.4199) | (0.4199) | (0.4199) | (0.4199) | (0.4199) | (188) | (1.3 K) | (601) | (0.5274) | (0.55) |
| KPRX | (679) | (679) | (679) | (436) | (153) | (817) | (906) | (556) | (183) | (89.2386) | (70.4953) | (68.0008) | (18.5492) | (23.2597) | (24.42) |
| FBRX | (474) | (474) | (474) | (474) | (474) | (474) | (635) | (999) | (915) | (48.2159) | (267) | (38.8536) | (19.9355) | (24.9248) | (26.17) |
| CLRB | (254.4 K) | (6.2 K) | (4.3 K) | (3.9 K) | (1.8 K) | (703) | (142) | (96.6574) | (44.6967) | (18.0772) | (7.448) | (4.3177) | (4.0537) | (3.1079) | (3.26) |
| TNXP | (578.4 K) | (578.4 K) | (3.5 K) | (3.5 K) | (3.5 K) | (3.5 K) | (3.5 K) | (3.5 K) | (3.5 K) | (3.5 K) | (3.5 K) | (1.6 K) | (640) | (219) | (230) |
| JAGX | (205 K) | (205 K) | (205 K) | (205 K) | (205 K) | (479.2 K) | (249.7 K) | (27.3 K) | (15.5 K) | (1.7 K) | (214) | (101) | (36.1816) | (107) | (113) |
| VXRT | (56.7599) | (7.0636) | (3.4695) | (3.8599) | (5.9416) | (7.2317) | (8.3686) | (3.2924) | (2.851) | (0.8644) | (0.3649) | (0.5802) | (0.8439) | (0.5694) | (0.6) |
| PULM | (0.1765) | (0.1765) | (131) | (766) | (766) | (647) | (376) | (186) | (99.6661) | (24.3709) | (19.8342) | (8.3088) | (5.4312) | (3.8667) | (4.06) |
| CAPR | (0.2) | (65.4297) | (1.9035) | (8.4674) | (5.3147) | (8.0853) | (10.1379) | 1.0483 | (5.17) | (1.9879) | (0.8657) | (0.8406) | (1.1819) | (0.8323) | (0.87) |
| AKTX | (5.0487) | (15.8492) | (11.5179) | (17.1767) | (11.2822) | (5.3184) | (1.5404) | (2.2388) | (1.2621) | (23.7728) | (11.1407) | (8.2043) | (2.2335) | (2.0447) | (2.15) |
| SLNO | (347) | (347) | (347) | (198) | (819) | (127) | (58.352) | (26.177) | (9.5361) | (15.7787) | (3.6829) | (5.5586) | (2.4198) | (2.364) | (2.48) |
AIM ImmunoTech and related stocks such as Aptorum Group, Applied Molecular, and Fresh Tracks Therapeutics Net Income Per Share description
My Equities
My Current Equities and Potential Positions
| AIM ImmunoTech | AIM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Florida; U.S.A |
| Exchange | NYSE MKT Exchange |
USD 0.2151
Check out AIM ImmunoTech Performance and AIM ImmunoTech Correlation. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
AIM ImmunoTech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.